H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data
H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.
How this was made
The 30-second read
Why it matters
The Phase 2a results provide the first robust efficacy signal, likely driving short‑term price appreciation.
Market read
Positive trial data and upgraded analyst targets create a clear catalyst for CADL's stock.
What to watch
Potential regulatory timeline and competition from other NSCLC therapies.
Background
Candel Therapeutics (NASDAQ:CADL) is a clinical‑stage biotech focused on oncolytic viral therapies.
Ticker impact
Candel Therapeutics released final Phase 2a NSCLC trial results showing median overall survival of 24.5 months, prompting analyst rating reiteration and price target increase.
potential upward pressure as investors price in improved survival outcomes.
Data exceeds historical benchmarks and analysts raised targets, indicating upside potential.
Market effects
strengthens biotech sector sentiment on immuno‑oncology pipelines.
U.S. biotech investors may see increased risk appetite.
limited to biotech investors, no broad market effect.
Counterpoint
Some may argue the data size is modest and valuation already high, suggesting caution.
Key entities
- companyCandel Therapeutics Inc.
Biotech developing CAN-2409 therapy.
- analystH.C. Wainwright
Equity research firm reiterating Buy rating.
